04-15-2019 06:48 PM CET - Business, Economy, Finances, Banking & Insurance
Print

Investigation announced for long-term investors in shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT)

Press release from: Shareholders Foundation
An investigation on behalf of investors in Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares over potential wrongdoing.
An investigation on behalf of investors in Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares over potential wrongdoing.


An investigation was announced on behalf of investors in shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) concerning possible breaches of fiduciary duties by certain officers and directors at Helius Medical Technologies, Inc.

Investors who purchased shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) and currently hold any of those NASDAQ: HSDT shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Helius Medical Technologies directors breached their fiduciary duties and caused damage to the company and its shareholders.

Newtown, PA based Helius Medical Technologies, Inc., a medical technology company, focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma.

On January 22, 2019, an article was published stating that Helius Medical Technologies’ phase III trial “missed its primary effectiveness endpoint” and that Helius “has redacted important trial info.” The article further states that the founders “have a history of questionable marketing practices” and that the former CEO “is now a fugitive.”

On April 10, 2019, Helius Medical Technologies’ disclosed that the U.S. Food and Drug Administration ("FDA") had declined the Company's request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies.

Shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) declined from $17.97 per share in October 2017 to as low as $1.77 per share on April 11, 2019.

Those who purchased shares of Helius Medical Technologies, Inc. (NASDAQ: HSDT) have certain options and should contact the Shareholders Foundation.

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

This release was published on openPR.
News-ID: 1703819 • Views: 294
More releasesMore releases

You can edit or delete your press release here: